Foster Announces 348 New Jobs and £54 Million Investment by Almac Group
Enterprise, Trade and Investment Minister Arlene Foster has announced that the Almac Group is investing over £54 million and creating 348 high quality jobs over the next 5 years.
The Almac Group operates in the pharmaceutical and biotechnology sectors providing services including drug discovery, diagnostics, research and development, manufacture of active pharmaceutical ingredients, formulation development and clinical trials.
It employs more than 2100 staff at its headquarters in Craigavon, with an additional 1380 staff located in facilities throughout the rest of the UK, US and Asia. The investment, supported by Invest Northern Ireland, relates to two of the Group’s operating business units, Pharma Services and Clinical Services.
Announcing the investment, Arlene Foster said: “Almac is one of Northern Ireland’s most successful indigenous companies and a globally respected brand. This significant investment will enable Almac to expand the range of services it can offer, allowing it to respond to key trends within the pharmaceutical industry and enhance its market-leading position.”
Almac Pharma Services provides contract development and manufacturing services to the world’s leading pharmaceutical and biotech companies. As well as recruiting 141 new staff over the next five years, the company will invest in new technologies and equipment to take advantage of the growing demand for outsourced development services.
Almac Clinical Services provides clinical packaging, labelling, logistics and clinical supply chain management services to the pharmaceutical industry. It is investing in cold chain storage and distribution facilities and enhanced information systems to capitalise on the demand from clients for closer partnering opportunities. The unit is creating 181 new jobs over the next 5 years.
The investments will also create a further 26 new jobs within the group.
“These 348 new jobs will generate salaries of over £9.4 million per annum when the projects are fully implemented. This is a significant cash injection for the local economy. The investments are also good news for our growing life sciences sector, which is gaining an international reputation for innovation and excellence,” added the Minister.
Invest NI has offered Almac Group £5.5 million of support towards its investment.
Alan Armstrong, Chairman and CEO of the Almac Group, said: “We are fortunate to employ an excellent highly-skilled workforce at our Craigavon headquarters which has played a major role in our global growth. It’s fantastic that demand for our services has resulted in the creation of so many new jobs as we embark on further expansion over the next 5 years.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.